The role of physical activity (PA) in cancer prevention is well recognized, with recent publications by the World Cancer Research Fund/American Institute for Cancer Research ([@pkz080-B1]) and the 2018 Physical Activity Guidelines for Americans Report highlighting its importance to global health ([@pkz080-B2]). Since the mid-2000s, there has been an exponential increase in studies evaluating the link between PA and survival outcomes that has resulted in some reviews on this topic ([@pkz080-B3]). Although published reviews have explored the relationship between PA and survival (cancer-specific or all-cause mortality) following breast ([@pkz080-B4]), colorectal ([@pkz080-B6],[@pkz080-B10]), or all cancer ([@pkz080-B11],[@pkz080-B12]), to date there have been no systematic reviews and meta-analyses examining *all* available cancer sites (including all-cancer as well as specific cancer sites) with cancer-specific and all-cause mortality outcomes. In addition, cardiovascular disease (CVD) is receiving increasing research attention as a leading cause of mortality for those with cancer. Yet, despite the known benefits through PA on CVD risk and survival, there are no available reviews evaluating cardiovascular mortality following any cancer.

In part, as a consequence of the exponential growth in PA and cancer survival epidemiological research, the momentum behind endorsing and promoting PA in the prevention and management of cancer has also grown ([@pkz080-B13]). Concurrently, however, concerns have been raised about whether there is sufficient evidence to support the benefits of PA participation for all people with cancer or, alternatively, whether the evidence supports benefit through PA only for specific cancer types or subgroups within cancer types (that is, is dependent on sex, body mass index (BMI), menopausal status, or subtypes within a specific cancer). In addition, the extent to which the evidence can guide recommendations around PA domain (ie, total, recreational \[leisure time\], occupational, household) and dose of PA and for whom is unclear ([@pkz080-B14]). Hence, there is a need for rigorous review of the rapidly evolving evidence base. As such, the primary objective of this systematic review and meta-analysis was to evaluate the association between prediagnosis and postdiagnosis PA and survival (primary outcomes: cancer-specific mortality, all-cause mortality, and CVD mortality) for all cancer and by specific cancer sites by using data from all available observational epidemiologic studies and randomized, controlled trials. Secondary objectives included assessing these associations by sex, BMI, menopausal status, and colorectal cancer subtype; evaluating the associations between different domains of PA (ie, total, recreational \[leisure time\], occupational, household) and survival outcomes; and determining the dose-response relationship between PA and cancer survival.

Methods
=======

This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([@pkz080-B15]). Additionally, the protocol was registered in PROSPERO (registration number: CRD42018103290).

Literature Search Strategy
--------------------------

PubMed, EMBASE, and SportDiscus were searched from inception to July 5, 2018, using the search strategy "(physical activity OR motor activity OR exercise) AND (cancer OR neoplasm\* OR carcinoma OR adenocarcinoma OR sarcoma OR tumor) AND (mortality OR recurrence OR progression OR outcome\* OR survival) AND (survivors OR survivor OR survivorship OR patients OR patient)." Keywords (including any associated synonyms) along with medical subject headings for PA, cancer, and mortality were included. There were no restrictions by date, language, or geographical region. Reference lists of all included studies and relevant review articles were searched manually to identify additional studies, and e-alert notifications in PubMed captured additional articles through November 1, 2018.

Eligibility Screening
---------------------

Eligibility was assessed independently and in duplicate using a two-stage process. First, two independent reviewers (CRS and ML, acknowledgments) screened title and abstracts of all captured literature. Studies were considered for full-text review if the title or abstract indicated that the exposure was PA and the outcome was related to survival outcomes following cancer (survival, mortality, recurrence, progression, etc) in human populations. If relevance was uncertain, the study was carried forward for full-text review. Second, two independent reviewers (CRS and either RKP, NM, or RU, acknowledgments) reviewed the remaining studies in their entirety. Inclusion criteria for full-text review were as follows: 1) the original peer-reviewed published research was available; 2) the exposure was PA, presented with a comparator group (ie, not continuously); 3) one or more mortality outcomes were reported (ie, cancer-specific mortality, all-cause mortality in cancer patients, CVD mortality in cancer patients); 4) the outcomes reported included a point estimate of risk, hazards, or odds ratios; 5) the study design was observational cohort or randomized trial (case reports and reviews were excluded).

Agreement between the two reviewers was quantified at the full-text review stage using percentage agreement and kappa statistics. Disagreements were resolved by consensus-based discussion between reviewers. In the event that there were multiple publications describing the same population with the same domain of PA exposure and mortality outcome, with no new subgroups of interest presented, the article presenting the largest sample size was retained in the review.

Data Extraction
---------------

A data collection form, developed specifically for this review, was used to extract and record author, publication year, study name, location, sample size, number of deaths, recruitment years, date of last follow-up, follow-up period, method of PA assessment, and outcome ascertainment source from eligible publications. We additionally extracted the following variables: cancer type, outcome type, timing of PA, domain of PA, high and low activity categories, activity units, hazard estimates and 95% confidence intervals for the highest vs lowest category of PA from the most adjusted model, population subgroups data on sex, BMI (kg/m^2^), menopausal status, and estimates by colorectal cancer subsite and by domain of PA. We calculated the reciprocal of the reported point estimate if the lowest vs the highest level of PA was presented. When "floating" confidence intervals were reported, we converted them to conventional confidence intervals with a reference category ([@pkz080-B16]). We contacted six authors (regarding eight papers) via e-mail up to two times to request information that was essential for meta-analysis; four authors replied.

Decision rules for data extraction were established to align with our primary aim and ensure consistent extraction of the exposure of interest: physical activity. For example, if multiple estimates were presented for different activity intensities, we extracted, in priority order, the point estimate for all intensities, moderately vigorous, vigorous, moderate, and finally light intensities. If multiple domains of PA were reported, we extracted, in priority order, the point estimate for total, recreational, occupational, and finally, household PA. If multiple estimates were presented for different life-periods prediagnosis, we extracted the estimate closest to diagnosis, rather than lifetime PA, to capture the short-term effects of exercise. Finally, if multiple estimates were provided for different units of activity, we extracted, in hierarchical order, the following: metabolic equivalent duration (MET; one MET is considered to be the resting metabolic rate achieved during quiet sitting \[[@pkz080-B17]\]), hours per week, energy expenditure (kilocalories or kilojoules), frequency (times per day), and ordinal or rank (ie, scale of 1--10, categories).

Study Quality Assessment
------------------------

A single reviewer (CRS) used the Newcastle-Ottawa Scale to assess the quality of each included study ([@pkz080-B18]). This scale assesses the quality of included studies with scores ranging from zero (indicating poor-quality studies) to nine (indicating high-quality studies). The scores come from three domains: selection, comparability, and outcome. The domain of selection was worth a maximum of four points based on sample selection (two points if the sample was representative of the exposed cohort and one point if the sample was composed of a selected group of individuals, ie, nurses, volunteers); ascertainment of exposure (one point if PA was ascertained through interview or actigraphy and zero points if self-administered); and outcome (one point if outcome was not present at start of study). The domain of comparability was worth a maximum of two points, with one point being awarded if models controlled for age, and an additional point awarded if models controlled for additional confounders. Finally, the domain of outcome was worth a maximum of three points based on outcome assessment (one point if outcome was obtained through record linkage), length of follow-up (one point if study had a follow-up time of more than three years), and loss to follow-up (one point if loss to follow-up was described, or if study had complete follow-up).

Statistical Analysis
--------------------

To account for heterogeneity within the included studies, estimates were combined only if they pertained to the same cancer type, outcome type (cancer-specific, all-cause, or CVD-specific mortality), and timing of PA (prediagnosis or postdiagnosis). To account further for the inherent between-study heterogeneity in the population of patients, we used DerSimonian and Laird random-effects models to derive summary estimates of hazards depicted graphically with forest plots ([@pkz080-B19]). Studies were represented once per meta-analysis except when results were only available for subgroup (ie, by sex). In these instances, each subgroup was treated as an independent study within random-effects models to acknowledge clinical heterogeneity and to reduce within-study confounding. Meta-regression and stratified analyses were performed to ensure that summary estimates did not differ by time-scale (ie, healthy cohorts vs cancer survivor cohorts) ([@pkz080-B20]). Sensitivity analyses were performed, removing each study one by one to examine the impact of combining randomized, controlled trials with observational studies. Subgroup meta-analyses were conducted across strata of cancer type, outcome type, and timing of PA by domain of PA (total, recreational and/or leisure time, transportation, occupational, household), BMI (\<25 kg/m^2^, ≥25 kg/m^2^), sex (male, female), menopausal status (premenopausal, postmenopausal; where studies presented results by age, we used a cut point of 55 years whereby younger than 55 years was classified as premenopausal and older than 55 years was classified as postmenopausal; limited to breast cancer), and colorectal cancer subsite (colon, rectum). Where there were sufficient studies presenting estimates based on recreational PA volume in MET hours per week, we performed random-effects dose-response analyses ([@pkz080-B21]). We applied the midpoint of each exposure category or the limit for open-ended exposure categories (eg, 10--20 was assigned a value of 15; \<3 was assigned a value of 1.5).

Heterogeneity was assessed using I^2^ statistics, which serve to describe the percentage of variation across studies due to heterogeneity rather than chance; I^2^ values of 25%, 50%, and 75% indicate low, moderate, and high levels of heterogeneity, respectively ([@pkz080-B22]). Publication bias was assessed pertaining to our primary objective with three or more estimates qualitatively through visual inspection of funnel plots and quantitatively using the Begg rank correlation test and Egger regression test for funnel plot asymmetry ([@pkz080-B23],[@pkz080-B24]). All analyses were conducted using Stata software (version 15.1; StataCorp LP, College Station, TX); *P* values less than .05 were considered to be statistically significant and all tests were two-sided.

Results
=======

Literature Search
-----------------

We identified 15 760 records from our database search, five from PubMed e-alerts, and 31 through other sources such as reference lists, relevant review articles, and literature summary documents maintained by authors ([Figure 1](#pkz080-F1){ref-type="fig"}). After removing duplicates, 11 996 titles or abstracts remained and 967 were eligible for full-text screening. Full-text screening by two independent reviewers resulted in 97.5% agreement on inclusion or exclusion (kappa = 0.857). A total of 136 studies remained for inclusion in this systematic review and meta-analysis.

![Flow diagram showing inclusion and exclusion of studies. PA = physical activity.](pkz080f1){#pkz080-F1}

Study Characteristics
---------------------

The study design, sample size, outcomes, and methods for PA assessment for the 136 included studies are shown in [Table 1](#pkz080-T1){ref-type="table"}. Of these, nine studies reported on multiple cancer sites, 38 on all-cancer sites combined, 39 on breast cancer, 19 on colorectal cancer, nine on prostate cancer, four each for ovarian and pancreatic cancers, three each on endometrial and hematologic cancers, two for lung cancer, and one each for bladder cancer, cervical, childhood, kidney cancers, malignant glioma, and melanoma. To improve the precision of our estimates, we combined cervical, endometrial, and ovarian cancers as "female reproductive" cancers and leukemia, lymphoma, myeloma, and other hematopoietic cancers as "hematologic" cancers. The included studies were primarily of high quality (scores \>7), with 38 studies receiving perfect scores on the Newcastle-Ottawa quality assessment ([Table 1](#pkz080-T1){ref-type="table"}). The most common reasons for reductions on the quality assessment scale were the use of self-administered questionnaires to report PA behaviors (56% of studies used participant-reported or retrospective data collection to ascertain PA levels) and having nonrepresentative population samples (15% of included studies).

###### 

Characteristics of the included studies in the systematic review and meta-analysis on physical activity and cancer mortality, by cancer site[\*](#tblfn1){ref-type="table-fn"}

  Author, year, country, reference                                                                                      Name of study                                                                                             Cancer type                                                                                                                                                                                                                No. deaths   No. with cancer   No. in analytic sample   Outcome type                               Physical activity assessment   Subgroups used                                  Quality score (of 9)
  --------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ----------------- ------------------------ ------------------------------------------ ------------------------------ ----------------------------------------------- ----------------------
  Studies assessing multiple sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
   Davey Smith, 2000, United Kingdom ([@pkz080-B25])                                                                    Whitehall Study                                                                                           All, lung, hematopoietic, stomach, pancreas                                                                                                                                                                                832          ---               6702                     Cancer-specific                            Prediagnosis                   ---                                             7
   Batty, 2001, United Kingdom ([@pkz080-B26])                                                                          Whitehall Study                                                                                           All, lung, colorectal, hematopoietic, stomach, pancreas, colorectal                                                                                                                                                        1499         ---               11 663                   Cancer-specific                            Prediagnosis                   CRC subsite                                     7
   Sundelof, 2008, Sweden ([@pkz080-B27])                                                                               Swedish Oesophageal and Cardia Cancer Study                                                               Esophagus, squamous cell, stomach                                                                                                                                                                                          ---          580               580                      All-cause                                  Prediagnosis                   ---                                             9
   Wen, 2011, Taiwan ([@pkz080-B28])                                                                                    ---                                                                                                       All, colorectal, liver, lung, breast                                                                                                                                                                                       2185         ---               416 175                  Cancer-specific                            Prediagnosis                   Age, sex                                        8
   Arem, 2014, United States ([@pkz080-B29])                                                                            National Institutes of Health--AARP Diet and Health Study                                                 All, lymphocytic leukemia, liver, oral cavity and pharynx, non-Hodgkin lymphoma, esophagus, myeloma, lung, myeloid/monocytic leukemia, stomach, ovarian, prostate, bladder, breast, brain, endometrial, pancreas, kidney   15 001       ---               293 511                  Cancer-specific                            Prediagnosis                   ---                                             8
   Okada, 2017, Japan ([@pkz080-B30])                                                                                   BioBank Japan Project                                                                                     Esophagus, stomach                                                                                                                                                                                                         816          1939              1939                     All-cause                                  Postdiagnosis                  ---                                             9
   Jee, 2018, Korea ([@pkz080-B31])                                                                                     Korean Metabolic Syndrome Mortality Study                                                                 All, esophagus, head and neck, liver, lung, colorectal, pancreas, kidney, stomach, prostate, breast, cervix                                                                                                                7539         ---               303 428                  Cancer-specific                            Prediagnosis                   No overall, by sex                              8
   Schmid, 2018, United States ([@pkz080-B32])                                                                          National Institutes of Health--AARP Diet and Health Study                                                 Hematologic, non-Hodgkin lymphoma, myeloma, leukemia                                                                                                                                                                       2606         5182              5182                     All-cause, cancer-specific                 Prediagnosis, postdiagnosis    Age, sex, BMI                                   8
   Tarasenko, 2018, United States ([@pkz080-B33])                                                                       National Health Interview Survey                                                                          All, breast, prostate, colorectal, uterine                                                                                                                                                                                 3528         13 997            13 997                   All-cause, cancer-specific, CVD-specific   Postdiagnosis                  ---                                             9
  Studies assessing only all-cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
   Arraiz, 1992, Canada ([@pkz080-B34])                                                                                 Canada Health Survey Mortality Follow-up Study                                                            All                                                                                                                                                                                                                        229          ---               12 917                   Cancer-specific                            Prediagnosis                   ---                                             9
   Kampert, 1996, United States ([@pkz080-B35])                                                                         Aerobics Center Longitudinal Study                                                                        All                                                                                                                                                                                                                        223          ---               32 421                   Cancer-specific                            Prediagnosis                   No overall, by sex                              7
   Rosengren, 1997, Sweden ([@pkz080-B36])                                                                              Multifactor Primary Prevention Study                                                                      All                                                                                                                                                                                                                        723          ---               7142                     Cancer-specific                            Prediagnosis                   Men only                                        8
   Kilander, 2001, Sweden ([@pkz080-B37])                                                                               ---                                                                                                       All                                                                                                                                                                                                                        216          ---               2285                     Cancer-specific                            Prediagnosis                   Men only                                        8
   Hu, 2005, Finland ([@pkz080-B38])                                                                                    ---                                                                                                       All                                                                                                                                                                                                                        2039         ---               47 212                   Cancer-specific                            Prediagnosis                   No overall, by sex                              8
   Schnohr, 2006, Denmark ([@pkz080-B39])                                                                               Copenhagen City Heart Study                                                                               All                                                                                                                                                                                                                        632          ---               4894                     Cancer-specific                            Prediagnosis                   ---                                             8
   Matthews, 2007, China ([@pkz080-B40])                                                                                Shanghai Women's Health Study                                                                             All                                                                                                                                                                                                                        537          ---               67 143                   Cancer-specific                            Prediagnosis                   Women only                                      9
   Orsini, 2008, Sweden ([@pkz080-B41])                                                                                 Cohort of Swedish Men                                                                                     All                                                                                                                                                                                                                        901          ---               37 633                   Cancer-specific                            Prediagnosis                   No overall, by BMI, men only                    8
   van Dam, 2008, United States ([@pkz080-B42])                                                                         Nurses' Health Study                                                                                      All                                                                                                                                                                                                                        4527         ---               77 782                   Cancer-specific                            Prediagnosis                   Women only                                      7
   Hamer, 2009, Scotland ([@pkz080-B43])                                                                                Scottish Health Surveys                                                                                   All                                                                                                                                                                                                                        78           293               293                      All-cause                                  Postdiagnosis                  Type of PA                                      9
   Autenrieth, 2011, Germany ([@pkz080-B44])                                                                            MONICA/KORA Augsburg Survey (S2)                                                                          All                                                                                                                                                                                                                        326          ---               4672                     Cancer-specific                            Prediagnosis                   Type of PA                                      9
   Borch, 2011, Norway ([@pkz080-B45])                                                                                  Norwegian Women and Cancer Cohort Study                                                                   All                                                                                                                                                                                                                        1584         ---               66 136                   Cancer-specific                            Prediagnosis                   Women only                                      8
   Laukkanen, 2011, Finland ([@pkz080-B46])                                                                             Eastern Finnish Follow-up Study                                                                           All                                                                                                                                                                                                                        181          ---               2560                     Cancer-specific                            Prediagnosis                   Men only                                        9
  McCullough, 2011, United States ([@pkz080-B47])                                                                       Cancer Prevention Study-II Nutrition Cohort                                                               All                                                                                                                                                                                                                        5874         ---               111 966                  Cancer-specific                            Prediagnosis                   No overall, by sex                              8
   Lin, 2012, Taiwan ([@pkz080-B48])                                                                                    Taichung Diabetes Study                                                                                   All                                                                                                                                                                                                                        122          ---               5686                     Cancer-specific                            Prediagnosis                   ---                                             8
   Mok, 2012, Korea ([@pkz080-B49])                                                                                     Severance Cohort Study                                                                                    All                                                                                                                                                                                                                        1060         3555              59 636                   Cancer-specific                            Prediagnosis                   No overall, by sex                              8
   Parekh, 2012, United States ([@pkz080-B50])                                                                          Third National Health and Nutrition Examination Survey                                                    All                                                                                                                                                                                                                        860          ---               15 535                   Cancer-specific                            Prediagnosis                   BMI                                             9
   Inoue-Choi, 2013, United States ([@pkz080-B51])                                                                      Iowa Women's Health Study                                                                                 All                                                                                                                                                                                                                        461          2017              2017                     All-cause, cancer-specific, CVD-specific   Postdiagnosis                  Women only                                      8
   Vergnaud, 2013, Europe ([@pkz080-B52])                                                                               European Prospective Investigation into Cancer and Nutrition                                              All                                                                                                                                                                                                                        9388         ---               378 864                  Cancer-specific                            Prediagnosis                   Sex                                             8
   Wang, 2013, China ([@pkz080-B53])                                                                                    Shanghai Men's Health Study                                                                               All                                                                                                                                                                                                                        1053         ---               61 477                   Cancer-specific                            Prediagnosis                   Men only                                        9
   Yu, 2013, China ([@pkz080-B54])                                                                                      ---                                                                                                       All                                                                                                                                                                                                                        452          ---               2867                     Cancer-specific                            Prediagnosis                   No overall, by sex                              8
   Gunnell, 2014, Australia ([@pkz080-B55])                                                                             Busselton Health Study                                                                                    All                                                                                                                                                                                                                        164          528               2320                     Cancer-specific                            Prediagnosis                   ---                                             8
   Hardee, 2014, United States ([@pkz080-B56])                                                                          Aerobics Center Longitudinal Study                                                                        All                                                                                                                                                                                                                        121          2863              2863                     All-cause                                  Postdiagnosis                  ---                                             8
   Hastert, 2014, United States ([@pkz080-B57])                                                                         Vitamins and Lifestyle Study                                                                              All                                                                                                                                                                                                                        1595         ---               57 841                   Cancer-specific                            Prediagnosis                   ---                                             8
   Lee, 2014, United States ([@pkz080-B58])                                                                             Harvard Alumni Health Study                                                                               All                                                                                                                                                                                                                        777          1021              1021                     All-cause, cancer-specific, CVD-specific   Postdiagnosis                  Men only                                        7
   Wanner, 2014, Switzerland ([@pkz080-B59])                                                                            MONICA/National Research Program 1A                                                                       All                                                                                                                                                                                                                        1351         ---               17 663                   Cancer-specific                            Prediagnosis                   Sex                                             8
   Brown, 2015, United States ([@pkz080-B60])                                                                           Third National Health and Nutrition Examination Survey                                                    All                                                                                                                                                                                                                        319          416               416                      All-cause                                  Prediagnosis                   ---                                             8
   Kabat, 2015, United States ([@pkz080-B61])                                                                           National Institutes of Health--AARP Diet and Health Study                                                 All                                                                                                                                                                                                                        16 193       73 784            476 396                  Cancer-specific                            Prediagnosis                   No overall, by sex                              8
  Kraschnewski, 2016, United States ([@pkz080-B62])                                                                     National Health Interview Survey                                                                          All                                                                                                                                                                                                                        ---          ---               30 162                   Cancer-specific                            Prediagnosis                   ---                                             7
   Lee, 2016, Korea ([@pkz080-B63])                                                                                     Kangbuk Samsung Health Study                                                                              All                                                                                                                                                                                                                        970          ---               336 560                  Cancer-specific                            Prediagnosis                   Age, sex, BMI                                   8
   Robsahm, 2016, Norway ([@pkz080-B64])                                                                                Oslo Ischemia Study                                                                                       All                                                                                                                                                                                                                        433          758               1997                     Cancer-specific                            Prediagnosis                   Men only, type of PA                            8
   Gunnell, 2017, Australia ([@pkz080-B65])                                                                             Western Australia Health and Wellbeing Surveillance System                                                All                                                                                                                                                                                                                        135          1589              4734                     All-cause, cancer-specific                 Postdiagnosis                  ---                                             9
   Kamada, 2017, United States ([@pkz080-B66])                                                                          Women's Health Study                                                                                      All                                                                                                                                                                                                                        748          ---               28 879                   Cancer-specific                            Prediagnosis                   Women only                                      8
   O'Donovan, 2017, United Kingdom ([@pkz080-B67])                                                                      Health Survey for England and Scottish Health Survey                                                      All                                                                                                                                                                                                                        2526         ---               63 591                   Cancer-specific                            Prediagnosis                   ---                                             9
  Vainshelboim, 2017, United States ([@pkz080-B68])                                                                     Veterans Exercise Testing Study                                                                           All                                                                                                                                                                                                                        447          1013              4034                     Cancer-specific                            Prediagnosis                   Men only                                        7
   Dohrn, 2018, Sweden ([@pkz080-B69])                                                                                  Sweden Attitude Behaviour and Change Study                                                                All                                                                                                                                                                                                                        27           ---               851                      Cancer-specific                            Prediagnosis                   ---                                             9
   Liu, 2018, China ([@pkz080-B70])                                                                                     Shanghai Men's Health Study and Shanghai Women's Health Study                                             All                                                                                                                                                                                                                        3512         ---               120 727                  Cancer-specific                            Prediagnosis                   Sex                                             9
   Patel, 2018, United States ([@pkz080-B71])                                                                           Cancer Prevention Study--II Nutrition Cohort                                                              All                                                                                                                                                                                                                        13 186       ---               139 255                  Cancer-specific                            Prediagnosis                   ---                                             8
  Studies assessing only bladder cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
   Liss, 2017, United States ([@pkz080-B72])                                                                            National Health Information Survey                                                                        Bladder                                                                                                                                                                                                                    83           ---               222 163                  Cancer-specific                            Prediagnosis                   ---                                             9
  Studies assessing only breast cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Rohan, 1995, Australia ([@pkz080-B73])                                                                               ---                                                                                                       Breast                                                                                                                                                                                                                     112          412               412                      Cancer-specific                            Prediagnosis                   Menopausal status                               9
   Borugian, 2004, Canada ([@pkz080-B74])                                                                               ---                                                                                                       Breast                                                                                                                                                                                                                     112          603               603                      Cancer-specific                            Prediagnosis                   Menopausal status                               8
   Enger, 2004, United States ([@pkz080-B75])                                                                           ---                                                                                                       Breast                                                                                                                                                                                                                     251          717               717                      Cancer-specific                            Prediagnosis                   ---                                             9
   Holmes, 2005, United States ([@pkz080-B76])                                                                          Nurses' Health Study                                                                                      Breast                                                                                                                                                                                                                     463          2987              2987                     All-cause, cancer-specific                 Postdiagnosis                  BMI, menopausal status                          7
  Abrahamson, 2006, United States ([@pkz080-B77])                                                                       ---                                                                                                       Breast                                                                                                                                                                                                                     290          1264              1264                     All-cause                                  Prediagnosis                   BMI                                             8
   Dal Maso, 2008, Italy ([@pkz080-B78])                                                                                ---                                                                                                       Breast                                                                                                                                                                                                                     503          1453              1453                     All-cause, cancer-specific                 Prediagnosis                   Type of PA                                      9
   Holick, 2008, United States ([@pkz080-B79])                                                                          Collaborative Women's Longevity Study                                                                     Breast                                                                                                                                                                                                                     412          4482              4482                     All-cause, cancer-specific                 Postdiagnosis                  BMI, age                                        8
   Irwin, 2008, United States ([@pkz080-B80])                                                                           Health, Eating, Activity, and Lifestyle Study                                                             Breast                                                                                                                                                                                                                     164          933               933                      All-cause, cancer-specific                 Prediagnosis, postdiagnosis    BMI, menopausal status                          9
  Friedenreich, 2009, Canada ([@pkz080-B81])                                                                            ---                                                                                                       Breast                                                                                                                                                                                                                     341          1225              1225                     All-cause, cancer-specific                 Prediagnosis                   Type of PA                                      9
   Sternfeld, 2009, United States ([@pkz080-B82])                                                                       Life After Cancer Epidemiology Study                                                                      Breast                                                                                                                                                                                                                     187          1970              1970                     All-cause, cancer-specific                 Postdiagnosis                  BMI                                             8
   West-Wright, 2009, United States ([@pkz080-B83])                                                                     California Teachers Study                                                                                 Breast                                                                                                                                                                                                                     460          3539              3539                     All-cause, cancer-specific                 Prediagnosis                   BMI                                             7
   Emaus, 2010, Norway ([@pkz080-B84])                                                                                  Norwegian Counties Study                                                                                  Breast                                                                                                                                                                                                                     429          1364              1364                     All-cause, cancer-specific                 Prediagnosis                   BMI, menopausal status                          8
   Hellmann, 2010, Denmark ([@pkz080-B85])                                                                              Copenhagen City Heart Study                                                                               Breast                                                                                                                                                                                                                     323          528               528                      All-cause, cancer-specific                 Prediagnosis                   Menopausal status                               8
   Keegan, 2010, United States, Canada, Australia ([@pkz080-B86])                                                       Breast Cancer Family Registry                                                                             Breast                                                                                                                                                                                                                     725          4153              4153                     All-cause                                  Prediagnosis                   BMI                                             8
   Bertram, 2011, United States ([@pkz080-B87])                                                                         Women's Healthy Eating and Living Study                                                                   Breast                                                                                                                                                                                                                     163          2361              2361                     All-cause                                  Postdiagnosis                  ---                                             8
   Chen, 2011, China ([@pkz080-B88])                                                                                    Shanghai Breast Cancer Survival Study                                                                     Breast                                                                                                                                                                                                                     436          4826              4826                     All-cause                                  Postdiagnosis                  BMI, menopausal status                          9
   Irwin, 2011, United States ([@pkz080-B89])                                                                           Women's Health Initiative                                                                                 Breast                                                                                                                                                                                                                     350          4643              4643                     All-cause, cancer-specific                 Prediagnosis, postdiagnosis    BMI                                             8
   Beasley, 2012, United States, China ([@pkz080-B9])                                                                   After Breast Cancer Pooling Project: LACE-NHS-SBCSS-WHEL                                                  Breast                                                                                                                                                                                                                     1468         13 302            13 302                   All-cause, cancer-specific                 Postdiagnosis                  BMI, menopausal status                          7
   Cleveland, 2012, United States ([@pkz080-B90])                                                                       Long Island Breast Cancer Study Project                                                                   Breast                                                                                                                                                                                                                     196          1508              1508                     All-cause, cancer-specific                 Prediagnosis                   BMI, menopausal status                          9
   Schmidt, 2013, Germany ([@pkz080-B91])                                                                               MARIE Study                                                                                               Breast                                                                                                                                                                                                                     367          3393              3393                     All-cause, cancer-specific                 Prediagnosis                   BMI                                             9
   Tao, 2013, United States ([@pkz080-B92])                                                                             Western New York Exposure and Breast Cancer Study                                                         Breast                                                                                                                                                                                                                     170          1170              1170                     All-cause, cancer-specific                 Prediagnosis                   ---                                             9
   Williams, 2013, United States ([@pkz080-B93])                                                                        National Runners' and Walkers' Health Survey                                                              Breast                                                                                                                                                                                                                     111          ---               79 124                   Cancer-specific                            Prediagnosis                   ---                                             7
   Bradshaw, 2014, United States ([@pkz080-B94])                                                                        Long Island Breast Cancer Study                                                                           Breast                                                                                                                                                                                                                     420          1423              1423                     All-cause, cancer-specific                 Postdiagnosis                  BMI                                             9
   Courneya, 2014, Canada ([@pkz080-B95])                                                                               Supervised Trial of Aerobic vs Resistance Training                                                        Breast                                                                                                                                                                                                                     24           242               242                      All-cause                                  Postdiagnosis                  ---                                             9
   de Glas, 2014, Netherlands ([@pkz080-B96])                                                                           Tamoxifen Exemestane Adjuvant Multicenter Lifestyle Study                                                 Breast                                                                                                                                                                                                                     80           521               521                      All-cause, cancer-specific                 Prediagnosis                   Age                                             6
   Keegan, 2014, United States ([@pkz080-B97])                                                                          Neighborhoods and Breast Cancer Study                                                                     Breast                                                                                                                                                                                                                     915          4345              4345                     All-cause, cancer-specific                 Prediagnosis                   ---                                             9
   Williams, 2014, United States ([@pkz080-B98])                                                                        National Runners' and Walkers' Health Survey                                                              Breast                                                                                                                                                                                                                     46           986               986                      Cancer-specific                            Postdiagnosis                  ---                                             7
   Bao, 2015, China ([@pkz080-B99])                                                                                     Shanghai Breast Cancer Survival Study                                                                     Breast                                                                                                                                                                                                                     128          518               518                      All-cause                                  Postdiagnosis                  Triple negative only                            9
   Borch, 2015, Norway ([@pkz080-B100])                                                                                 Norwegian Women and Cancer Cohort Study                                                                   Breast                                                                                                                                                                                                                     197          1327              1327                     All-cause, cancer-specific                 Prediagnosis, postdiagnosis    BMI, menopausal status                          8
   Lu, 2015, United States ([@pkz080-B101])                                                                             California Breast Cancer Survivorship Consortium                                                          Breast                                                                                                                                                                                                                     1347         4608              4608                     All-cause, cancer-specific                 Prediagnosis                   BMI, menopausal status                          9
   Pinkston, 2015, United States ([@pkz080-B102])                                                                       New Mexico Women's Health Study                                                                           Breast                                                                                                                                                                                                                     240          540               1283                     All-cause, cancer-specific                 Prediagnosis                   No overall, by race and type of PA              9
   Ammitzboll 2016, Denmark ([@pkz080-B103])                                                                            Diet, Cancer and Health Study                                                                             Breast                                                                                                                                                                                                                     144          959               959                      All-cause                                  Postdiagnosis                  Type of PA                                      7
   Jones, 2016, United States ([@pkz080-B104])                                                                          Life After Cancer Epidemiology and Pathways studies                                                       Breast                                                                                                                                                                                                                     405          6211              6211                     Cancer-specific                            Postdiagnosis                  ---                                             8
  McCullough, 2017, United States ([@pkz080-B105])                                                                      Long Island Breast Cancer Study                                                                           Breast                                                                                                                                                                                                                     486          1254              1254                     All-cause, cancer-specific                 Prediagnosis                   ---                                             7
   Cifu, 2018, United States ([@pkz080-B106])                                                                           National Institutes of Health--AARP Diet and Health Study                                                 Breast                                                                                                                                                                                                                     1162         7088              7088                     Cancer-specific                            Prediagnosis                   ---                                             8
   Hayes, 2018, Australia ([@pkz080-B107])                                                                              Exercise for Health Trials                                                                                Breast                                                                                                                                                                                                                     26           337               337                      All-cause                                  Postdiagnosis                  BMI, menopausal status                          7
   Maliniak, 2018, United States ([@pkz080-B108])                                                                       Cancer Prevention Study-II Nutrition Cohort                                                               Breast                                                                                                                                                                                                                     1771         5254              5254                     All-cause, cancer-specific                 Prediagnosis, postdiagnosis    No overall, by age                              8
   Palesh, 2018, United States ([@pkz080-B109])                                                                         ---                                                                                                       Breast                                                                                                                                                                                                                     93           103               103                      All-cause                                  Postdiagnosis                  ---                                             8
   Parada, 2019, United States ([@pkz080-B110])                                                                         Carolina Breast Cancer Study                                                                              Breast                                                                                                                                                                                                                     717          1808              1808                     All-cause                                  Prediagnosis                   ---                                             9
  Studies assessing only cervical cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Kim, 2016, Korea ([@pkz080-B111])                                                                                    ---                                                                                                       Cervical                                                                                                                                                                                                                   30           860               860                      All-cause                                  Postdiagnosis                  ---                                             8
  Studies assessing only childhood cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   Scott, 2018, United States Canada ([@pkz080-B112])                                                                   Childhood Cancer Survivor Study                                                                           Childhood cancer                                                                                                                                                                                                           1063         15 450            15 450                   All-cause, CVD-specific                    Postdiagnosis                  ---                                             8
  Studies assessing only colorectal cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Meyerhardt, 2006, United States ([@pkz080-B113])                                                                     Nurses' Health Study                                                                                      Colorectal                                                                                                                                                                                                                 132          573               573                      All-cause, cancer-specific                 Prediagnosis; postdiagnosis    Women only, age, BMI, colon vs rectum           7
   Huxley, 2007, China, Hong Kong, Japan, Korea, Singapore, Taiwan, Thailand, Australia, New Zealand ([@pkz080-B114])   Asia Pacific Cohort Studies Collaboration                                                                 Colorectal                                                                                                                                                                                                                 751          ---               539 201                  Cancer-specific                            Prediagnosis                   ---                                             6
   Meyerhardt, 2009, United States ([@pkz080-B115])                                                                     Health Professionals Follow-Up Study                                                                      Colorectal                                                                                                                                                                                                                 258          668               668                      All-cause, cancer-specific                 Postdiagnosis                  Men only                                        7
   Baade, 2011, Australia ([@pkz080-B116])                                                                              ---                                                                                                       Colorectal                                                                                                                                                                                                                 462          1825              1825                     All-cause, CVD-specific                    Postdiagnosis                  Age, sex, BMI, colon vs rectum                  8
   Morrison, 2011, United Kingdom ([@pkz080-B117])                                                                      Whitehall Study                                                                                           Colorectal                                                                                                                                                                                                                 450          ---               17 949                   Cancer-specific                            Prediagnosis                   No overall, by colon vs rectum                  7
   Kuiper, 2012, United States ([@pkz080-B118])                                                                         Women's Health Initiative                                                                                 Colorectal                                                                                                                                                                                                                 265          1339              1339                     All-cause, cancer-specific                 Prediagnosis, postdiagnosis    Women only                                      8
   Boyle, 2013, Australia ([@pkz080-B119])                                                                              Western Australia Bowel Health Study                                                                      Colorectal                                                                                                                                                                                                                 224          879               879                      All-cause, cancer-specific                 Prediagnosis                   Sex, colon vs rectum                            8
   Campbell, 2013, United States ([@pkz080-B120])                                                                       Cancer Prevention Study-II Nutrition Cohort                                                               Colorectal                                                                                                                                                                                                                 846          2293              2293                     All-cause, cancer-specific, CVD-specific   Prediagnosis, postdiagnosis    Age, sex, BMI, colon vs rectum                  8
   Pelser, 2014, United States ([@pkz080-B121])                                                                         National Institutes of Health--AARP Diet and Health Study                                                 Colorectal                                                                                                                                                                                                                 1727         5727              5727                     All-cause, cancer-specific, CVD-specific   Prediagnosis,                  No overall, by colon vs rectum                  8
   Arem, 2015, United States ([@pkz080-B122])                                                                           National Institutes of Health--AARP Diet and Health Study                                                 Colorectal                                                                                                                                                                                                                 1541         3797              3797                     All-cause, cancer-specific, CVD-specific   Prediagnosis, postdiagnosis    ---                                             8
   Hardikar, 2015, United States ([@pkz080-B123])                                                                       Colon Cancer Family Registry-Seattle                                                                      Colorectal                                                                                                                                                                                                                 408          1309              1309                     All-cause, cancer-specific                 Prediagnosis                   Colon vs rectum                                 8
   Romaguera, 2015, Europe ([@pkz080-B124])                                                                             European Prospective Investigation into Cancer and Nutrition                                              Colorectal                                                                                                                                                                                                                 1113         3292              3292                     All-cause, cancer-specific                 Prediagnosis                   ---                                             8
   Mok, 2016, Korea ([@pkz080-B125])                                                                                    Korean Metabolic Syndrome Mortality Study                                                                 Colorectal                                                                                                                                                                                                                 469          ---               226 089                  Cancer-specific                            Prediagnosis                   No overall, by sex, colon vs rectum, age, BMI   8
   Thong, 2016, Netherlands ([@pkz080-B126])                                                                            Patient-Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship registry   Colorectal                                                                                                                                                                                                                 249          1552              1552                     All-cause                                  Postdiagnosis                  ---                                             6
   Ratjen, 2017, Germany ([@pkz080-B127])                                                                               ---                                                                                                       Colorectal                                                                                                                                                                                                                 200          1376              1376                     All-cause                                  Postdiagnosis                  Type of PA, sex, age, BMI, colon vs rectum      8
   Walter, 2017, Germany ([@pkz080-B128])                                                                               DACHS Study                                                                                               Colorectal                                                                                                                                                                                                                 868          3121              3121                     All-cause, cancer-specific                 Prediagnosis                   Age, sex, colon vs rectum, BMI                  9
   Jayasekara, 2018, Australia ([@pkz080-B129])                                                                         Melbourne Collaborative Cohort Study                                                                      Colorectal                                                                                                                                                                                                                 339          724               724                      All-cause, cancer-specific                 Prediagnosis                   Colon vs rectum                                 9
   Phipps, 2018, United States ([@pkz080-B130])                                                                         North Central Cancer Treatment Group N0147                                                                Colorectal                                                                                                                                                                                                                 505          1992              1992                     All-cause                                  Prediagnosis                   Colon only                                      7
   van Blarigan, 2018, United States ([@pkz080-B131])                                                                   Cancer and Leukemia Group B 89803                                                                         Colorectal                                                                                                                                                                                                                 299          992               992                      All-cause                                  Postdiagnosis                  Colon only                                      8
  Studies assessing only endometrial cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Arem, 2013, United States ([@pkz080-B132])                                                                           National Institutes of Health--AARP Diet and Health Study                                                 Endometrial                                                                                                                                                                                                                312          1400              1400                     All-cause                                  Prediagnosis                   ---                                             8
   Arem, 2013, United States ([@pkz080-B133])                                                                           Women's Health Initiative                                                                                 Endometrial                                                                                                                                                                                                                163          983               983                      All-cause, cancer-specific                 Prediagnosis                   ---                                             8
   Arem, 2016, United States ([@pkz080-B134])                                                                           National Institutes of Health--AARP Diet and Health Study                                                 Endometrial                                                                                                                                                                                                                91           580               580                      All-cause                                  Postdiagnosis                  ---                                             8
  Studies assessing only malignant glioma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   Ruden, 2011, United States ([@pkz080-B135])                                                                          ---                                                                                                       Malignant glioma                                                                                                                                                                                                           149          243               243                      All-cause                                  Postdiagnosis                  ---                                             7
  Studies assessing only hematologic cancers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Wiskemann, 2015, Germany ([@pkz080-B136])                                                                            ---                                                                                                       Leukemia                                                                                                                                                                                                                   44           103               103                      All-cause                                  Postdiagnosis                  ---                                             6
   Boyle, 2017, Canada ([@pkz080-B137])                                                                                 ---                                                                                                       Lymphoma                                                                                                                                                                                                                   169          413               413                      All-cause, cancer-specific                 Prediagnosis                   ---                                             6
   Pophali, 2018, United States ([@pkz080-B138])                                                                        Lymphoma SPORE Molecular Epidemiology Resource                                                            Lymphoma                                                                                                                                                                                                                   863          3060              3060                     All-cause, cancer-specific                 Prediagnosis                   ---                                             8
  Studies assessing only kidney cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Schmid, 2018, United States ([@pkz080-B139])                                                                         National Institutes of Health--AARP Diet and Health Study                                                 Kidney                                                                                                                                                                                                                     175          667               667                      All-cause, cancer-specific                 Postdiagnosis                  ---                                             8
  Studies assessing only lung cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Jones, 2012, United States ([@pkz080-B140])                                                                          ---                                                                                                       Lung                                                                                                                                                                                                                       77           118               118                      All-cause                                  Postdiagnosis                  ---                                             7
   Sloan, 2016, United States ([@pkz080-B141])                                                                          Mayo Clinic Epidemiology and Genetics of Lung Cancer Research Program                                     Lung                                                                                                                                                                                                                       512          1466              1466                     All-cause                                  Postdiagnosis                  ---                                             7
  Studies assessing only melanoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
   Schwitzer, 2017, Australia, Canada, Italy, United States ([@pkz080-B142])                                            Genes, Environment and Melanoma Study                                                                     Melanoma                                                                                                                                                                                                                   341          2465              2465                     All-cause, cancer-specific                 Prediagnosis                   ---                                             9
  Studies assessing only ovarian cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
   Yang, 2008, Sweden ([@pkz080-B143])                                                                                  ---                                                                                                       Ovarian                                                                                                                                                                                                                    396          635               635                      Cancer-specific                            Prediagnosis                   ---                                             8
   Moorman, 2011, United States ([@pkz080-B144])                                                                        North Carolina Ovarian Cancer Study                                                                       Ovarian                                                                                                                                                                                                                    238          638               1321                     All-cause                                  Prediagnosis                   ---                                             9
  Zhou, 2014, United States ([@pkz080-B145])                                                                            Women's Health Initiative                                                                                 Ovarian                                                                                                                                                                                                                    346          600               600                      All-cause, cancer-specific                 Prediagnosis                   ---                                             8
  Abbott, 2018, United States ([@pkz080-B146])                                                                          African American Cancer Epidemiology Study                                                                Ovarian                                                                                                                                                                                                                    80           264               264                      All-cause                                  Prediagnosis, postdiagnosis    ---                                             9
  Studies assessing only pancreatic cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Lee, 2003, United States ([@pkz080-B147])                                                                            College Alumni Health Study                                                                               Pancreatic                                                                                                                                                                                                                 212          ---               32 687                   Cancer-specific                            Prediagnosis                   ---                                             7
   Lin, 2007, Japan ([@pkz080-B148])                                                                                    Japanese Collaborative Cohort Study                                                                       Pancreatic                                                                                                                                                                                                                 402          ---               100 932                  Cancer-specific                            Prediagnosis                   No overall, by sex                              8
   Stevens, 2009, United Kingdom ([@pkz080-B149])                                                                       Million Women Study                                                                                       Pancreatic                                                                                                                                                                                                                 1710         ---               1 290 000                Cancer-specific                            Prediagnosis                   Women only                                      8
   Nakamura, 2011, Japan ([@pkz080-B150])                                                                               Takayama Study                                                                                            Pancreatic                                                                                                                                                                                                                 52           ---               30 826                   Cancer-specific                            Prediagnosis                   No overall, by sex                              8
  Studies assessing only prostate cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Nilsen, 2006, Norway ([@pkz080-B151])                                                                                HUNT Study (Norway)                                                                                       Prostate                                                                                                                                                                                                                   354          957               29 110                   Cancer-specific                            Prediagnosis                   ---                                             8
   Crespo, 2008 ([@pkz080-B152]) Puerto Rico                                                                            Puerto Rico Heart Health Program                                                                          Prostate                                                                                                                                                                                                                   167          ---               9780                     Cancer-specific                            Prediagnosis                   BMI, age                                        9
   Orsini, 2009, Sweden ([@pkz080-B153])                                                                                Cohort of Swedish Men                                                                                     Prostate                                                                                                                                                                                                                   190          ---               45 887                   Cancer-specific                            Prediagnosis                   Type of PA                                      8
   Batty, 2011, United Kingdom ([@pkz080-B154])                                                                         Whitehall Study                                                                                           Prostate                                                                                                                                                                                                                   578          ---               17 934                   Cancer-specific                            Prediagnosis                   Type of PA                                      7
   Kenfield, 2011, United States ([@pkz080-B155])                                                                       Health Professionals Follow-Up Study                                                                      Prostate                                                                                                                                                                                                                   548          2705              2705                     All-cause, cancer-specific                 Postdiagnosis                  ---                                             7
   Bonn, 2015, Sweden ([@pkz080-B156])                                                                                  Progression in Cancer of the Prostate                                                                     Prostate                                                                                                                                                                                                                   561          4623              4623                     All-cause, cancer-specific                 Postdiagnosis                  Type of PA                                      8
  Friedenreich, 2016, Canada ([@pkz080-B157])                                                                           ---                                                                                                       Prostate                                                                                                                                                                                                                   458          830               830                      All-cause, cancer-specific                 Prediagnosis, postdiagnosis    Type of PA                                      9
   Tai, 2016, Taiwan ([@pkz080-B158])                                                                                   ---                                                                                                       Prostate                                                                                                                                                                                                                   48           608               608                      Cancer-specific                            Prediagnosis                   ---                                             7
   Wang, 2017, United States ([@pkz080-B159])                                                                           Cancer Prevention Study-II Nutrition Cohort                                                               Prostate                                                                                                                                                                                                                   454          7328              7328                     All-cause, cancer-specific                 Prediagnosis, postdiagnosis    ---                                             8

BMI = body mass index; CRC = colorectal cancer; CVD = cardiovascular disease; PA = physical activity.

Primary Results
---------------

[Figures 2](#pkz080-F2){ref-type="fig"} and [3](#pkz080-F3){ref-type="fig"} display forest plots of the summary hazard ratios for the highest vs lowest amount of prediagnosis and postdiagnosis PA for all cancers and specific cancer sites on cancer-specific mortality and all-cause mortality, respectively. Evidence from 136 studies contributed to findings showing reduced hazards of mortality for those in the highest vs lowest levels of prediagnosis and/or postdiagnosis total or recreational PA for all cancers combined (cancer-specific mortality: hazard ratio \[HR\] = 0.82, 95% confidence interval \[CI\] = 0.79 to 0.86, and HR = 0.63, 95% CI = 0.53 to 0.75, respectively). Statistically significantly reduced hazards were also found for 11 cancer types depending on timing of PA (prediagnosis and postdiagnosis) and mortality outcome (cancer-specific and all-cause mortality). Specifically, higher prediagnosis PA was protective against cancer-specific mortality following breast, colorectal, hematologic, liver, lung, and stomach cancer, and higher postdiagnosis PA was protective against cancer-specific mortality following breast, colorectal, and prostate cancer ([Figure 2](#pkz080-F2){ref-type="fig"}). For all-cause mortality, higher prediagnosis PA was protective against breast, colorectal, hematologic, and prostate cancer, and higher postdiagnosis PA was protective following breast, childhood, colorectal, gynecologic, glioma, hematologic, kidney, lung, prostate, and stomach cancer ([Figure 3](#pkz080-F3){ref-type="fig"}). Breast and colorectal cancer sites had the largest number of contributing studies, and results suggest that greater reductions were observed for postdiagnosis PA both for cancer-specific and all-cause mortality (HR = 0.58--0.63) compared with mortality reductions observed with prediagnosis PA (HR = 0.80--0.86). Summary estimates did not differ by time scale ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}, available online), and thus healthy cohorts and cancer survival cohorts were combined in the results. Further, removal of randomized, controlled trials did not change the results (data not shown).
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When considering the association between PA and CVD mortality and given the small number of studies, prediagnosis and postdiagnosis PA were combined to create a single estimate. The summary hazard ratios for all-cancer (n = 3), childhood cancer (n = 1), and colorectal cancer (n = 4) were 0.60 (95% CI = 0.50--0.73), 0.89 (95% CI = 0.49--1.61), and 0.60 (95% CI = 0.40--0.91), respectively. No cancer sites were found to have statistically significant increased mortality hazards (for any mortality outcome) associated with higher levels of PA ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}, available online).

After visual examination of funnel plots and *P* values from the Begg and Egger tests, there was evidence for publication bias only for postdiagnosis PA and colorectal cancer-specific mortality (*P* \< .05) (results not shown).

Subgroup Analysis Results
-------------------------

Subgroup analyses by sex, BMI, menopausal status (in breast cancer), and colorectal subtype are presented in [Table 2](#pkz080-T2){ref-type="table"}. Overall, hazards of cancer-specific and all-cause mortality for those undertaking higher vs lower prediagnosis and/or postdiagnosis PA were reduced both for men and women (all cancers and within colorectal cancer), those with lower BMI (\<25 kg/m^2^; for all cancers, and within breast and colorectal but not within prostate cancer), prediagnosis and postmenopausal women (except for the association for premenopausal women and breast cancer-specific mortality), and colorectal subtypes, with trends toward stronger effect for postdiagnosis PA (HR = 0.37--0.88) vs prediagnosis PA (HR = 0.75--1.53).There was some suggestion (based on differences in effect size observed across colorectal, breast, and hematological cancer groups) that benefit through postdiagnosis PA to all-cause mortality survival was greater for those with BMI less than 25 kg/m^2^ (HR = 0.49--0.57; all *P* \< .05) compared with those with BMI greater than 25 kg/m^2^ (HR = 0.64--0.71; *P* \< .05--0.112).

###### 

Subgroup meta-analyses of the association between physical activity and cancer mortality, separately by sex, BMI, menopausal status, and colorectal subsite[\*](#tblfn2){ref-type="table-fn"}

  Subgroup                                   Prediagnosis physical activity   Postdiagnosis physical activity                                                          
  ----------------------------------------- -------------------------------- --------------------------------- -------- -------- ------ --------------------- -------- --------
  Cancer-specific mortality                                                                                                                                            
   Sex                                                                                                                                                                 
    All cancers (male)                                   18/18                      0.80 (0.74 to 0.87)        \<.001   75.50%    1/1    0.62 (0.44 to 0.87)  .006     --
    All cancers (female)                                 16/16                      0.86 (0.79 to 0.93)        \<.001   61.70%    1/1    0.72 (0.47 to 1.10)  .130     --
    Colorectal (male)                                     3/3                       0.85 (0.53 to 1.34)        .478     76.50%    2/2    0.70 (0.38 to 1.28)  .247     66.60%
    Colorectal (female)                                   5/5                       0.67 (0.54 to 0.84)        .001     0.00%     3/3    0.50 (0.27 to 0.90)  .020     58.10%
  BMI                                                                                                                                                                  
   All cancers (\<25 kg/m^2^)                             3/3                       0.77 (0.62 to 0.96)        .018     0.00%      --            --           --       --
   All cancers (≥25 kg/m^2^)                              2/2                       0.91 (0.66 to 1.25)        .568     0.00%      --            --           --       --
   Breast (\<25 kg/m^2^)                                  4/4                       0.92 (0.58 to 1.23)        .56      42.60%    7/7    0.59 (0.44 to 0.78)  \<.001   49.70%
   Breast (≥25 kg/m^2^)                                   4/4                       0.76 (0.48 to 1.22)        .258     73.40%    7/8    0.61 (0.50 to 0.75)  \<.001   50.20%
   Colorectal (\<25 kg/m^2^)                              2/3                       0.75 (0.59 to 0.96)        .021     19.20%    2/2    0.37 (0.07 to 1.94)  .239     71.80%
   Colorectal (≥25 kg/m^2^)                               2/3                       0.79 (0.61 to 1.02)        .070     0.00%     2/2    0.78 (0.34 to 1.66)  .485     66.80%
   Prostate (\<25 kg/m^2^)                                1/1                       1.07 (0.55 to 2.11)        .844     --         --            --           --       --
   Prostate (≥25 kg/m^2^)                                 1/1                       1.53 (0.81 to 2.91)        .192     --         --            --           --       --
  Menopausal status                                                                                                                                                    
    Breast (premenopausal)                                5/5                       1.11 (0.90 to 1.37)        .310     0.00%     5/5    0.65 (0.47 to 0.89)  .008     45.50%
    Breast (postmenopausal)                               7/7                       0.93 (0.79 to 1.09)        .347     0.00%     7/7    0.68 (0.55 to 0.84)  \<.001   48.60%
  Colorectal subsite                                                                                                                                                   
    Colon                                                 8/9                       0.94 (0.80 to 1.11)        .448     34.80%    2/2    0.76 (0.58 to 0.99)  .044     0.00%
    Rectum                                                8/9                       0.79 (0.67 to 0.94)        .007     0.00%     2/2    0.60 (0.19 to 1.88)  .378     71.00%
  All-cause mortality in cancer survivors                                                                                                                              
   Sex                                                                                                                                                                 
    All cancers (male)                                     --                               --                 --       --        1/1    0.52 (0.42 to 0.65)  \<.001   --
    All cancers (female)                                   --                               --                 --       --        1/1    0.62 (0.47 to 0.83)  .001     --
    Colorectal (male)                                     3/3                       0.73 (0.62 to 0.87)        \<.001   0.00%     3/3    0.67 (0.56 to 0.80)  \<.001   0.00%
    Colorectal (female)                                   5/5                       0.73 (0.59 to 0.91)        .006     18.00%    4/4    0.45 (0.30 to 0.68)  \<.001   49.40%
  BMI                                                                                                                                                                  
   Breast (\<25 kg/m^2^)                                  7/7                       0.74 (0.60 to 0.91)        .005     56.70%    7/7    0.49 (0.35 to 0.68)  \<.001   64.20%
   Breast (≥25 kg/m^2^)                                   7/8                       0.81 (0.71 to 0.93)        .002     0.00%     7/11   0.70 (0.60 to 0.82)  \<.001   24.30%
   Colorectal (\<25 kg/m^2^)                              1/1                       0.78 (0.58 to 1.05)        .101     --        2/2    0.57 (0.45 to 0.73)  \<.001   0.00%
   Colorectal (≥25 kg/m^2^)                               2/2                       0.73 (0.58 to 0.92)        .009     0.00%     2/3    0.71 (0.47 to 1.08)  .112     38.60%
   Hematologic (\<25 kg/m^2^)                             1/1                       0.80 (0.67 to 0.96)        .015     --        1/1    0.54 (0.36 to 0.79)  .002     --
   Hematologic (≥25 kg/m^2^)                              1/1                       0.83 (0.74 to 0.93)        .001     --        1/1    0.64 (0.50 to 0.82)  \<.001   --
  Menopausal status                                                                                                                                                    
    Breast (premenopausal)                                4/4                       0.86 (0.61 to 1.22)        .394     30.70%    4/4    0.77 (0.58 to 1.02)  .065     28.60%
    Breast (postmenopausal)                               6/6                       0.81 (0.70 to 0.94)        .006     31.50%    5/5    0.69 (0.63 to 0.77)  \<.001   0.00%
  Colorectal subsite                                                                                                                                                   
    Colon                                                 7/7                       0.84 (0.71 to 0.99)        .037     56.60%    3/3    0.56 (0.42 to 0.75)  \<.001   42.30%
    Rectum                                                6/6                       0.84 (0.70 to 1.00)        .056     23.00%    2/2    0.88 (0.67 to 1.14)  .321     0.00%

BMI = body mass index; CI = confidence interval; HR = hazard ratio.

PA Domain Results
-----------------

Additional subgroup analyses by domain of PA (total, recreational, transportation, occupational, and household) are presented in [Table 3](#pkz080-T3){ref-type="table"}. For prediagnosis PA, the domains of recreational and total PA estimates were consistently associated with reduced hazards of mortality for all-cancer, breast, and colorectal cancer-specific mortality (*P* \< .05). Results remained inconsistent for the less-studied domains of transportation, occupational, and household PA (HR = 0.64--1.65).

###### 

Subgroup meta-analyses of the association between physical activity and cancer mortality, separately by domain of physical activity[\*](#tblfn3){ref-type="table-fn"}

  Site                                      PA type           No. of studies/ No. of estimates       HR (95% CI)        *P*     *I* ^2^   No. of studies/ No. of estimates  HR (95% CI)             *P*     *I* ^2^
  ----------------------------------------- ---------------- ---------------------------------- --------------------- -------- --------- ---------------------------------- --------------------- -------- ---------
  Cancer-specific mortality                                                                                                                                                                                
   All                                      Total                          12/16                 0.83 (0.75 to 0.92)   \<.001   48.10%                  2/2                 0.66 (0.50 to 0.86)     .002     0.00%
  Recreational                              24/27                   0.82 (0.77 to 0.86)                \<.001          68.20%     2/2           0.50 (0.24 to 1.02)         .057                   67.80%  
  Transportation                            2/2                     0.94 (0.82 to 1.07)                 .362           0.00%      ---                   ---                 ---                     ---    
  Occupational                              2/2                     1.18 (0.70 to 1.98)                 .530           61.00%     ---                   ---                 ---                     ---    
  Household                                 1/1                     0.90 (0.54 to 1.49)                 .684            ---       ---                   ---                 ---                     ---    
   Breast                                   Total                           5/6                  0.79 (0.63 to 0.99)    .043     0.00%                  3/3                 0.75 (0.47 to 1.21)     .236     0.00%
  Recreational                              19/21                   0.84 (0.75 to 0.94)                 .002           35.40%    10/11          0.61 (0.47 to 0.78)         \<.001                 70.40%  
  Transportation                            ---                             ---                          ---            ---       ---                   ---                 ---                     ---    
  Occupational                              2/2                     1.03 (0.80 to 1.33)                 .802           0.00%      ---                   ---                 ---                     ---    
  Household                                 1/1                     1.25 (0.81 to 1.94)                 .317            ---       ---                   ---                 ---                     ---    
   Colorectal                               Total                           2/2                  0.84 (0.73 to 0.96)    .010     0.00%                  1/1                 0.88 (0.68 to 1.15)     .340      ---
  Recreational                              10/12                   0.78 (0.70 to 0.87)                \<.001          0.00%      5/7           0.48 (0.34 to 0.67)         \<.001                 10.50%  
  Transportation                            1/2                     1.00 (0.63 to 1.58)                 .989           0.00%      ---                   ---                 ---                     ---    
  Occupational                              ---                             ---                          ---            ---       ---                   ---                 ---                     ---    
  Household                                 ---                             ---                          ---            ---                             ---                 ---                     ---    
   Prostate                                 Total                           3/3                  0.94 (0.70 to 1.27)    .697     7.20%                  2/2                 0.55 (0.36 to 0.87)     .010     0.00%
  Recreational                              7/7                     0.85 (0.70 to 1.04)                 .108           44.70%     3/3           0.71 (0.56 to 0.91)         .007                   14.30%  
  Transportation                            1/1                     1.65 (0.87 to 3.14)                 .127            ---       1/1           0.64 (0.43 to 0.95)         .025                    ---    
  Occupational                              2/2                     0.89 (0.59 to 1.35)                 .580           0.00%      1/1           0.90 (0.53 to 1.54)         .700                    ---    
  Household                                 1/1                     0.78 (0.49 to 1.24)                 .294            ---       2/2           1.02 (0.76 to 1.36)         .911                   0.00%   
  All-cause mortality in cancer survivors                                                                                                                                                                  
   All                                      Total                           ---                          ---            ---       ---                   3/3                 0.55 (0.47 to 0.65)    \<.001    0.00%
                                            Recreational                    1/1                  0.47 (0.29 to 0.75)    .002      ---                   5/5                 0.63 (0.50 to 0.79)    \<.001   50.80%
                                            Transportation                  ---                          ---            ---       ---                   ---                 ---                     ---       ---
                                            Occupational                    ---                          ---            ---       ---                   ---                 ---                     ---       ---
                                            Household                       ---                          ---            ---       ---                   1/1                 1.04 (0.60 to 1.80)     .889      ---
   Breast                                   Total                           5/6                  0.84 (0.67 to 1.05)    .126    32.80%                  6/6                 0.60 (0.47 to 0.75)    \<.001    0.00%
                                            Recreational                   16/18                 0.81 (0.76 to 0.87)   \<.001   16.70%                 11/12                0.58 (0.51 to 0.66)    \<.001   47.10%
                                            Transportation                  ---                          ---            ---       ---                   ---                 ---                     ---       ---
                                            Occupational                    2/2                  1.09 (0.88 to 1.35)    .421     0.00%                  ---                 ---                     ---       ---
                                            Household                       1/1                  1.46 (1.02 to 2.09)    .039      ---                   1/1                 0.93 (0.55 to 1.55)     .784      ---
   Colorectal                               Total                           2/2                  0.92 (0.80 to 1.06)    .237     0.00%                  3/3                 0.77 (0.57 to 1.03)     .080    84.60%
                                            Recreational                    8/8                  0.76 (0.70 to 0.84)   \<.001    0.00%                  7/9                 0.58 (0.49 to 0.69)    \<.001   11.60%
                                            Transportation                  ---                          ---            ---       ---                   ---                 ---                     ---       ---
                                            Occupational                    ---                          ---            ---       ---                   ---                 ---                     ---       ---
                                            Household                       ---                          ---            ---       ---                   1/1                 0.83 (0.55 to 1.23)     .364      ---
   Prostate                                 Total                           1/1                  1.02 (0.77 to 1.35)    .89                             2/2                 0.47 (0.31 to 0.71)    \<.001   68.90%
                                            Recreational                    2/2                  0.87 (0.80 to 0.96)    .004     0.00%                  4/4                 0.69 (0.56 to 0.85)    \<.001   71.80%
                                            Transportation                  ---                          ---            ---       ---                   1/1                 0.64 (0.43 to 0.94)     .025      ---
                                            Occupational                    1/1                  1.35 (1.00 to 1.81)    .047      ---                   1/1                 0.64 (0.47 to 0.91)     .011      ---
                                            Household                       1/1                  0.91 (0.70 to 1.18)    .474      ---                   2/2                 0.82 (0.70 to 0.97)     .023     0.00%

CI = confidence interval; HR = hazard ratio; PA = physical activity.

Dose-Response Analyses
----------------------

We restricted the analysis of dose-response to breast cancer studies because few studies examined these associations for other cancer sites. There was a linear association between prediagnosis PA dose and all-cause mortality (*P* for nonlinearity = .53) ([Figure 4C](#pkz080-F4){ref-type="fig"}). Evidence of nonlinear associations was found (*P* for nonlinearity \<.05) between prediagnosis and postdiagnosis PA and breast cancer-specific mortality ([Figure 4, A and B](#pkz080-F4){ref-type="fig"}, respectively) and postdiagnosis PA and all-cause mortality ([Figure 4D](#pkz080-F4){ref-type="fig"}). As seen in [Figure 4B](#pkz080-F4){ref-type="fig"}, the dose-response curve for postdiagnosis PA and all-cause mortality shows the largest reductions in mortality. Compared with no recreational PA, 5, 10, 20, 30, and 65 MET hours per week reduced all-cause mortality by 22%, 43%, 59%, 69%, and 108%, respectively. The steep reductions in mortality seen in [Figure 4, A, B, and D](#pkz080-F4){ref-type="fig"}, become less pronounced when PA dose is 10--15 MET hours per week or greater. The upper bounds of [Figure 4C](#pkz080-F4){ref-type="fig"} are less precise because of few contributing studies at higher levels of PA.

![Random-effects dose-response curves for recreational physical activity in breast cancer survivors. **A**) Prediagnosis physical activity and breast cancer-specific mortality (n = 7 sets of data from six studies); **B**) postdiagnosis physical activity and breast cancer-specific mortality (n = 7 sets of data from six studies); **C**) prediagnosis physical activity and all-cause mortality (n = 5 sets of data from four studies); **D**) postdiagnosis physical activity and all-cause mortality (n = 8 sets of data from seven studies). MET = metabolic equivalent.](pkz080f4){#pkz080-F4}

Discussion
==========

In this first ever analysis, to our knowledge, of the association between PA and cancer survival that included all cancer sites, we found evidence from 136 studies conducted to date for improved survival outcomes for all cancer and 11 cancer sites associated with prediagnosis or postcancer diagnosis PA. Although the most consistent and strong evidence for a role of PA in cancer survival was found for breast and colorectal cancer, there is also clear evidence for improved prostate cancer-specific survival with postdiagnosis PA. In addition, there is emerging evidence for a beneficial effect of prediagnosis PA on cancer-specific survival for liver, lung, hematologic, esophageal, and stomach cancers. Compared with prediagnosis PA, postdiagnosis PA was associated with greater reductions both in cancer-specific and all-cause mortality, with greater than 30% reductions in hazards for all-cause mortality observed in studies of all cancer, breast, colorectal, female reproductive, glioma, kidney, lung, prostate, and stomach cancers (HR = 0.58--0.76).

This study extends the results found in previous meta-analyses of PA and cancer survival ([@pkz080-B5],[@pkz080-B6],[@pkz080-B8]), with our results for breast and colorectal cancer similar in magnitude to those previously reported ([@pkz080-B4],[@pkz080-B10]) (prediagnosis and postdiagnosis PA HR = ∼ 0.80 and 0.60, respectively, for cancer-specific and all-cause mortality). Findings reported here also indicate that PA contributes to survival benefits for prostate, lung, liver, hematologic, stomach, esophageal, and female reproductive cancers. Conversely, there was no evidence of harm from higher PA levels, even for cancers associated with poor prognosis (eg, lung cancer) or melanoma, which is the only cancer site for which higher levels of PA have been associated with higher risk of development.

Using data from studies involving women with breast cancer, we found a nonlinear relationship between increasing postdiagnosis PA levels and breast cancer-specific and all-cause mortality hazards, up to about 10--15 MET hours per week. This level is consistent with approximately 150 weekly minutes of moderate-intensity PA or 75 weekly minutes of vigorous-intensity PA and fits with the amount of PA recommended by the World Health Organization for healthy adults ([@pkz080-B160]). This amount of PA is also typically endorsed and recommended by international cancer and clinical groups for those with cancer ([@pkz080-B13]). Our findings also suggest that the clinical relevance of any potential survival benefit accrued through PA levels beyond 15 MET hours per week becomes less clear.

Questions remain regarding what represents the optimal dose, domain, and timing of activity for people with cancer and what these associations are for specific cancer sites or population subgroups. Findings from this meta-analysis show that there is clear evidence that postdiagnosis PA is an important independent prognostic factor distinct from prediagnosis activity levels. In addition, there is some preliminary evidence from three RCTs that exercise during treatment is also an important predictor of mortality outcomes ([@pkz080-B95],[@pkz080-B107],[@pkz080-B136]). PA is also beneficial, irrespective of menopausal status, BMI, and sex, although being overweight or obese may attenuate the survival benefit. These findings highlight the need to combine weight (particularly fat mass) loss and PA interventions postcancer for those with BMIs greater than 25 kg/m^2^. Currently, there are insufficient data to support specific recommendations related to domain and dose of activity. For example, from a survival perspective, these epidemiologic findings support a PA dose of at least 10 METs, but not whether that dose is accumulated through recreational, transportation, occupational, or household activity, or mixed mode (aerobic vs resistance vs combined exercise) or specific intensity (moderate vs vigorous vs mixed). Nonetheless, findings are sufficiently compelling to support additional epidemiologic research, particularly on understudied cancer sites, subgroups within cancer sites, and more comprehensive measurement of PA (including during and posttreatment and domain, type, intensity, duration, and frequency). Further, these findings support the need for adequately powered, randomized, controlled exercise interventions that seek to evaluate the impact of modifying recreational PA on cancer outcomes ([@pkz080-B161]).

The magnitude of the effect of PA on cancer-specific and all-cause mortality outcomes ranged from 0.46 to 1.19 for prediagnosis PA and cancer-specific survival, whereas for postdiagnosis activity the range was narrower and stronger (0.57--0.79 for cancer-specific survival). The range of effect sizes observed was similar for prediagnosis and postdiagnosis activity when considering all-cause mortality outcomes. For prediagnosis activity, estimates ranged from 0.47 to 0.92, and for postdiagnosis, the range was 0.37--0.96. Of interest, however, was that for cancer sites for which there were greater than 10 contributing point estimates (which occurred for all cancers combined, breast, colorectal, and prostate cancers), there was greater consistency of the evidence. This range of effect sizes for cancer-specific survival was reduced to 0.80--0.90 for prediagnosis PA and 0.62--0.70 for postdiagnosis PA, and for all-cause survival, the range was 0.80--0.82 for prediagnosis PA and 0.58--0.63 for postdiagnosis PA. Hence, as the evidence base is accumulating, despite differences in study populations, study designs, and PA assessment methods, there is remarkable consistency of the effects of prediagnosis and postdiagnosis PA across various cancer sites.

Despite the exponential increase in the number of studies conducted on this topic since the mid-2000s, there is still a paucity of evidence for most cancer sites with only breast, colorectal, and prostate cancers approaching the number of studies required per site for meta-analyses by site and within population subgroups. To understand whether current differences observed in effect size are cancer specific or due to imprecision, more research beyond these top three cancer sites is needed. Additional limitations of this meta-analysis include the heterogeneous PA assessment methods. We mitigated, as much as possible, the impact of different PA assessment methods by selecting, wherever possible, point estimates expressed in units of MET hours per week. In addition, differences in adjustment for confounding and examination of effect modification also make comparisons across studies more challenging and can adversely influence the precision of summary estimates reported. We examined this issue with our quality assessment of the 136 included studies, which determined that these studies, overall, had high quality of conduct, adding credibility to the findings reported here.

We were unable to examine the associations between PA and cancer recurrence, progressions, or other cancer outcomes because of the heterogeneous definitions used across the source studies. Likewise, an interest in precision exercise oncology is to examine how cancer population subgroups, defined by clinical or pathologic characteristics, respond to PA ([@pkz080-B165]). To date, few studies have examined these clinicopathologic subgroups to identify which populations might benefit more from PA. With additional research on this topic and the prerequisite that future studies follow standardized definitions of outcomes (eg, STEEP guidelines) and comprehensively report patient and tumor characteristics, analyses by specific outcomes will also be possible and highly informative ([@pkz080-B166]). Finally, future studies are needed that use the highest quality of PA assessment with objective and self-report measures and the reporting in MET hours per week to permit additional evaluations of the dose-response effects in other cancer sites.

In summary, we found strong evidence that PA before or after cancer diagnosis was associated with statistically significant decreased hazards of cancer-specific and all-cause mortality in at least 11 different cancer sites. In addition, we found that hazard of CVD mortality among cancer survivors was also reduced with PA. As such, these findings confirm the importance of promoting PA after cancer and suggest that in doing so, there is huge potential for patient and public health gain through PA.
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